{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:53:34Z","timestamp":1791320014407,"version":"4.3.1"},"reference-count":99,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.retram.2022.103343","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T23:33:19Z","timestamp":1648164799000},"page":"103343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease"],"prefix":"10.1016","volume":"70","author":[{"given":"Faraat","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anam","family":"Ilyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.retram.2022.103343_bib0001","article-title":"REZUROCK (belumosudil) tablets, FDA Approved for Treatment of Chronic Graft-Versus-Host Disease, Available at Biologics by McKesson","author":"Crye","year":"2021","journal-title":"mckesson.com"},{"issue":"22","key":"10.1016\/j.retram.2022.103343_bib0002","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.retram.2022.103343_bib0003","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.20.02754","article-title":"ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease","volume":"39","author":"Jagasia","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.retram.2022.103343_bib0004","article-title":"U.S. FDA Grants Full Approval of REZUROCK\u2122 (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)","author":"Cavaleri","year":"2021","journal-title":"Kadmon Holdings, Inc."},{"key":"10.1016\/j.retram.2022.103343_bib0005","article-title":"FDA approves belumosudil for chronic graft-versus-host disease","year":"2021","journal-title":"FDA.GOV"},{"key":"10.1016\/j.retram.2022.103343_bib0006","article-title":"FDA green light for Rezurock in chronic graft-versus-host disease","year":"2021","journal-title":"The pharma letter"},{"key":"10.1016\/j.retram.2022.103343_bib0007","article-title":"Graft vs Host Disease: An Overview in Bone Marrow Transplant","year":"2020","journal-title":"Cleveland clinic"},{"issue":"6","key":"10.1016\/j.retram.2022.103343_bib0008","first-page":"504","article-title":"Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis","volume":"27","author":"Bachier","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.retram.2022.103343_bib0009","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","article-title":"Chronic graft-versus-host disease","volume":"9","author":"Lee","year":"2003","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.retram.2022.103343_bib0010","article-title":"FDA Approves Belumosudil to Treat Chronic Graft-Versus-Host Disease","year":"2021","journal-title":"National Cancer Institute"},{"issue":"26","key":"10.1016\/j.retram.2022.103343_bib0011","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.retram.2022.103343_bib0012","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/bbmt.2003.49999","article-title":"Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study","volume":"9","author":"Akpek","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.retram.2022.103343_bib0013","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.bbmt.2015.05.020","article-title":"Impact of ocular chronic graft-versus-host disease on quality of life","volume":"21","author":"Sun","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.retram.2022.103343_bib0014","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V57.2.267.267","article-title":"Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression","volume":"522","author":"Sullivan","year":"1981","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.retram.2022.103343_bib0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2016-07-686642","article-title":"Classification systems for chronic graft-versus-host disease","volume":"129","author":"Lee","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.retram.2022.103343_bib0016","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1021\/acs.jmedchem.5b00683","article-title":"Rho kinase (ROCK) inhibitors and their therapeutic potential","volume":"59","author":"Feng","year":"2016","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.retram.2022.103343_bib0017","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/FJC.0b013e318070d1bd","article-title":"Rho kinase (ROCK) inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"10.1016\/j.retram.2022.103343_bib0018","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tips.2010.12.006","article-title":"Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease","volume":"32","author":"Zhou","year":"2011","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.retram.2022.103343_bib0019","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acn3.19","article-title":"Selective ROCK 2 inhibition in focal cerebral ischemia","volume":"1","author":"Hyun Lee","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.retram.2022.103343_bib0020","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fnmol.2011.00039","article-title":"ROCKing regeneration: Rho kinase inhibition as molecular target for neurorestoration","volume":"4","author":"T\u00f6nges","year":"2011","journal-title":"Front Mol Neurosci"},{"issue":"6","key":"10.1016\/j.retram.2022.103343_bib0021","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3390\/molecules25061369","article-title":"Determination of KD025 (SLx-2119), a selective ROCK2 inhibitor, in rat plasma by high-performance liquid chromatography-tandem mass spectrometry and its pharmacokinetic application","volume":"25","author":"Yoon","year":"2020","journal-title":"Mol"},{"issue":"15-16","key":"10.1016\/j.retram.2022.103343_bib0022","first-page":"622","article-title":"Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases","volume":"15","author":"Dong","year":"2010","journal-title":"Drug Discov"},{"key":"10.1016\/j.retram.2022.103343_bib0023","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fneur.2020.00173","article-title":"Compassionate use of the ROCK inhibitor fasudil in three patients with amyotrophic lateral sclerosis","author":"Koch","year":"2020","journal-title":"Front Neurol"},{"issue":"8","key":"10.1016\/j.retram.2022.103343_bib0024","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3390\/ph14080710","article-title":"Innovations and patent trends in the development of USFDA approved protein kinase inhibitors in the last two decades","volume":"14","author":"Imran","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.retram.2022.103343_bib0025","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5045\/kjh.2011.46.2.80","article-title":"The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma","volume":"46","author":"Min","year":"2011","journal-title":"Korean J Hematol"},{"key":"10.1016\/j.retram.2022.103343_bib0026","article-title":"Rho Kinase Inhibitors","author":"Halfpenny","year":"2021","journal-title":"American Academy of ophthalmology"},{"issue":"47","key":"10.1016\/j.retram.2022.103343_bib0027","doi-asserted-by":"crossref","first-page":"16814","DOI":"10.1073\/pnas.1414189111","article-title":"Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism","volume":"111","author":"Zanin-Zhorov","year":"2014","journal-title":"Proc Natl Acad Sci"},{"issue":"17","key":"10.1016\/j.retram.2022.103343_bib0028","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood-2015-10-678706","article-title":"Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism","volume":"127","author":"Flynn","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.retram.2022.103343_bib0029","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/aos.12599","article-title":"Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study","volume":"93","author":"Tanihara","year":"2015","journal-title":"Acta Ophthalmol"},{"issue":"18","key":"10.1016\/j.retram.2022.103343_bib0030","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s40265-014-0333-2","article-title":"Ripasudil: first global approval","volume":"74","author":"KP","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.retram.2022.103343_bib0031","article-title":"PhaseI\/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients with Retinopathy of Prematurity. Kyushu University","author":"Arima","year":"2020","journal-title":"NCT04621136"},{"key":"10.1016\/j.retram.2022.103343_bib0032","author":"Macsai","year":"2017","journal-title":"Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy"},{"key":"10.1016\/j.retram.2022.103343_bib0033","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.2147\/OPTH.S154001","article-title":"Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date","volume":"12","author":"Dasso","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.retram.2022.103343_bib0034","series-title":"Rhopressa (netarsudil) Ophthalmic Solution","year":"2018"},{"key":"10.1016\/j.retram.2022.103343_bib0035","article-title":"Safety and Efficacy Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Subjects with Open Angle Glaucoma or Ocular Hypertension","author":"Aso","year":"2020","journal-title":"Aerie Pharmaceuticals. NCT04620135"},{"key":"10.1016\/j.retram.2022.103343_bib0036","article-title":"A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients with Corneal Edema Due to Fuchs Corneal Dystrophy (Fuchs)","author":"Senchyna","year":"2020","journal-title":"Aerie Pharmaceuticals. NCT04498169"},{"key":"10.1016\/j.retram.2022.103343_bib0037","article-title":"Study of Netarsudil Ophthalmic Solution in Subjects with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)","author":"Ramirez-Davis","year":"2017","journal-title":"Aerie Pharmaceuticals. NCT03233308"},{"key":"10.1016\/j.retram.2022.103343_bib0038","article-title":"Nocturnal\/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution","author":"Heah","year":"2016","journal-title":"Aerie Pharmaceuticals. NCT02874846"},{"key":"10.1016\/j.retram.2022.103343_bib0039","article-title":"Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects with Glaucoma or Ocular Hypertension","author":"Heah","year":"2015","journal-title":"Aerie Pharmaceuticals. NCT02558374"},{"key":"10.1016\/j.retram.2022.103343_bib0040","article-title":"Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients with Glaucoma or Ocular Hypertension","author":"Heah","year":"2014","journal-title":"Aerie Pharmaceuticals. NCT02246764"},{"key":"10.1016\/j.retram.2022.103343_bib0041","article-title":"Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients with Glaucoma and Ocular Hypertension","author":"Heah","year":"2014","journal-title":"Aerie Pharmaceuticals. NCT02207621"},{"key":"10.1016\/j.retram.2022.103343_bib0042","article-title":"Double-masked Study of AR-13324 Ophthalmic Solution in Patients with Glaucoma or Ocular Hypertension (Rocket-1)","author":"Heah","year":"2014","journal-title":"Aerie Pharmaceuticals. NCT02207491"},{"key":"10.1016\/j.retram.2022.103343_bib0043","article-title":"Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects with Open-angle Glaucoma or Ocular Hypertension in Japan","author":"Aso","year":"2019","journal-title":"Aerie Pharmaceuticals. NCT03844945"},{"key":"10.1016\/j.retram.2022.103343_bib0044","article-title":"Study of AR-13324 in Patients with Elevated Intraocular Pressure","author":"Heah","year":"2012","journal-title":"Aerie Pharmaceuticals. NCT01528787"},{"key":"10.1016\/j.retram.2022.103343_bib0045","article-title":"Study of Netarsudil Ophthalmic Solution in Japanese\/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension","author":"Ramirez-Davis","year":"2017","journal-title":"Aerie Pharmaceuticals. NCT03310580"},{"issue":"5","key":"10.1016\/j.retram.2022.103343_bib0046","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajo.2011.04.012","article-title":"Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension","volume":"152","author":"Williams","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.retram.2022.103343_bib0047","doi-asserted-by":"crossref","first-page":"e807","DOI":"10.1097\/IJG.0000000000000508","article-title":"Efficacy of topically administered rho-kinase inhibitor AR-12286 in patients with exfoliation syndrome and ocular hypertension or glaucoma","volume":"25","author":"Skaat","year":"2016","journal-title":"J Glaucoma"},{"key":"10.1016\/j.retram.2022.103343_bib0048","article-title":"A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma (ROCK)","author":"Ritch","year":"2013","journal-title":"LLC. NCT01936389"},{"key":"10.1016\/j.retram.2022.103343_bib0049","article-title":"A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients with Elevated Intraocular Pressure for 3 Months","author":"Levy","year":"2012","journal-title":"Aerie Pharmaceuticals. NCT01699464"},{"key":"10.1016\/j.retram.2022.103343_bib0050","article-title":"A Study of AR-12286 in Patient with Elevated Intraocular Pressure (IOP)","author":"Haarlem","year":"2009","journal-title":"Aerie Pharmaceuticals. NCT00902200"},{"key":"10.1016\/j.retram.2022.103343_bib0051","article-title":"Study of AR-12286 versus Latanoprost in Patients with Elevated Intraocular Pressure","author":"Haarlem","year":"2010","journal-title":"Aerie Pharmaceuticals. NCT01060579"},{"key":"10.1016\/j.retram.2022.103343_bib0052","article-title":"AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure","year":"2011","journal-title":"Aerie Pharmaceuticals. NCT01474135"},{"key":"10.1016\/j.retram.2022.103343_bib0053","article-title":"Fasudil","year":"2021","journal-title":"Science Direct"},{"key":"10.1016\/j.retram.2022.103343_bib0054","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1164\/rccm.200405-637OC","article-title":"Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension","volume":"171","author":"NAGAOKA","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.retram.2022.103343_bib0055","article-title":"Fasudil Hydrochloride Hydrate","year":"2016","journal-title":"pharmacodia.com"},{"key":"10.1016\/j.retram.2022.103343_bib0056","article-title":"Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction","author":"Pu","year":"2018","journal-title":"RenJi Hospital. NCT03753269"},{"key":"10.1016\/j.retram.2022.103343_bib0057","series-title":"Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS (ROCK-ALS)","author":"Lingor","year":"2019"},{"key":"10.1016\/j.retram.2022.103343_bib0058","series-title":"A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's phenomenon","author":"Wigley","year":"2007"},{"key":"10.1016\/j.retram.2022.103343_bib0059","article-title":"Fasudil Eye Drop in Retinopathy of Prematurity (ROP)","author":"Khah","year":"2019","journal-title":"Shahid Beheshti University of Medical Sciences. NCT04191954"},{"key":"10.1016\/j.retram.2022.103343_bib0060","article-title":"The Effect of Fasudil on Vascular Function in Humans","author":"Creager","year":"2005","journal-title":"Brigham and Women's Hospital. NCT00120718"},{"issue":"19","key":"10.1016\/j.retram.2022.103343_bib0061","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1158\/0008-5472.CAN-12-0954","article-title":"RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer","volume":"72","author":"Patel","year":"2012","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.retram.2022.103343_bib0062","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00417-018-4175-6","article-title":"RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis","volume":"257","author":"Dang","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.retram.2022.103343_bib0063","article-title":"Phase I Study of AT13148, a Novel AGC Kinase Inhibitor","year":"2012","journal-title":"Cancer Research UK. NCT01585701"},{"key":"10.1016\/j.retram.2022.103343_bib0064","year":"2021","journal-title":"AT13148. MedChemExpress"},{"key":"10.1016\/j.retram.2022.103343_bib0065","article-title":"A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability","author":"Singh","year":"2021","journal-title":"Kadmon Corporation. NCT04735822"},{"key":"10.1016\/j.retram.2022.103343_bib0066","article-title":"REZUROCK\u2122 (belumosudil) Tablets Approved to Treat Adult and Paediatric Patients 12 Years and Older with Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Lines of Therapy","year":"2021","journal-title":"Businesswire.com"},{"key":"10.1016\/j.retram.2022.103343_bib0067","year":"2021","journal-title":"Rezurock\u2122 (belumosudil) Is Available from Onco360! Onco360.com"},{"key":"10.1016\/j.retram.2022.103343_bib0068","article-title":"Kadmon Announces U.S. Availability of REZUROCK\u2122 (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)","year":"2021","journal-title":"[Press Release]"},{"key":"10.1016\/j.retram.2022.103343_bib0069","article-title":"Kadmon Announces FDA Acceptance of NDA for Belumosudil in Patients with Chronic Graft-Versus-Host Disease","year":"2020","journal-title":"[Press Release]"},{"key":"10.1016\/j.retram.2022.103343_bib0070","article-title":"FDA Grants Orphan Drug Designation to Kadmon's Belumosudil for the Treatment of Systemic Sclerosis","year":"2020","journal-title":"[Press Release]"},{"key":"10.1016\/j.retram.2022.103343_bib0071","article-title":"Kadmon and Meiji Announce Collaboration to Develop and Commercialize KD025 in Japan","year":"2019","journal-title":"[Press Release]"},{"key":"10.1016\/j.retram.2022.103343_bib0072","article-title":"Kadmon Establishes Strategic Partnership with BioNova to Develop and Commercialize KD025 for the Treatment of GVHD in China","year":"2019","journal-title":"[Press Release]"},{"key":"10.1016\/j.retram.2022.103343_bib0073","year":"2021","journal-title":"REZUROCK. rxlist.com."},{"key":"10.1016\/j.retram.2022.103343_bib0074","author":"Bartolozzi","year":"2006","journal-title":"Surface Logix, Inc. WO 2006105081 A2,"},{"key":"10.1016\/j.retram.2022.103343_bib0075","author":"Kim","year":"2012","journal-title":"Surface Logix, Inc. WO2012040499 A2"},{"key":"10.1016\/j.retram.2022.103343_bib0076","author":"Bartolozzi","year":"2008","journal-title":"Surface Logix, Inc. WO 2008054599 A2"},{"key":"10.1016\/j.retram.2022.103343_bib0077","author":"Nagarathnam","year":"2003","journal-title":"Bayer Corporation. US 20030087919A1"},{"key":"10.1016\/j.retram.2022.103343_bib0078","author":"Bankston","year":"2003","journal-title":"US 20030220357 A1"},{"key":"10.1016\/j.retram.2022.103343_bib0079","volume":"A2","author":"Kim","year":"2012","journal-title":"(Surface Logix, Inc.) WO"},{"key":"10.1016\/j.retram.2022.103343_bib0080","year":"2022","journal-title":"Medscape"},{"key":"10.1016\/j.retram.2022.103343_bib0081","year":"2022","journal-title":"Drug bank"},{"key":"10.1016\/j.retram.2022.103343_bib0082","article-title":"Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy","year":"2018","journal-title":"Kadmon Corporation. NCT03640481"},{"issue":"3","key":"10.1016\/j.retram.2022.103343_bib0083","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.retram.2022.103343_bib0084","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.retram.2022.103343_bib0085","article-title":"FDA Approves Rezurock to Treat Chronic Graft-Versus-Host Disease","year":"2021","journal-title":"Clinical Oncology News"},{"key":"10.1016\/j.retram.2022.103343_bib0086","article-title":"Rezurock Approved for Chronic Graft-vs-Host Disease","author":"Park","year":"2021","journal-title":"empr.com"},{"key":"10.1016\/j.retram.2022.103343_bib0087","article-title":"Efficacy and Safety of Belumosudil in Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSC)","year":"2020","journal-title":"Kadmon Corporation. NCT04680975"},{"key":"10.1016\/j.retram.2022.103343_bib0088","article-title":"A Phase 2 Study of the Efficacy and Safety of Belumosudil in Subjects with Moderate\/Severe Chronic Plaque Psoriasis","year":"2016","journal-title":"Kadmon Corporation. NCT02852967"},{"key":"10.1016\/j.retram.2022.103343_bib0089","article-title":"KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis","year":"2019","journal-title":"Kadmon Corporation. NCT03919799"},{"key":"10.1016\/j.retram.2022.103343_bib0090","article-title":"A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects with Chronic Graft Versus Host Disease","year":"2016","journal-title":"Kadmon Corporation. NCT02841995"},{"key":"10.1016\/j.retram.2022.103343_bib0091","article-title":"KD025 Hepatic Impairment Study with Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment","author":"Schueller","year":"2019","journal-title":"Kadmon Corporation. NCT04166942"},{"key":"10.1016\/j.retram.2022.103343_bib0092","article-title":"Efficacy and Safety of BN101 in Subjects with Chronic Graft Versus Host Disease (cGVHD)","author":"Prof Wu","year":"2021","journal-title":"BioNova Pharmaceuticals. NCT04930562."},{"key":"10.1016\/j.retram.2022.103343_bib0093","article-title":"A Phase 2 Study of the Activity and Safety of KD025 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)","year":"2016","journal-title":"Kadmon Corporation. NCT02688647"},{"key":"10.1016\/j.retram.2022.103343_bib0094","author":"Rezurock","year":"2021","journal-title":"drugs.com"},{"key":"10.1016\/j.retram.2022.103343_bib0095","year":"2022","journal-title":"rezurock.com"},{"key":"10.1016\/j.retram.2022.103343_bib0096","article-title":"FDA Approves Rezurock for Chronic Graft-Versus-Host Disease After Two Prior Lines of Therapy","author":"Dobkowski","year":"2021","journal-title":"Cure today"},{"key":"10.1016\/j.retram.2022.103343_bib0097","series-title":"European Medicine Agency Science Medicine Health","year":"2019"},{"key":"10.1016\/j.retram.2022.103343_bib0098","article-title":"Radar on Market Access: Rezurock Is Approved with More Transplant Agents in Pipeline","year":"2022","journal-title":"MMIT Network"},{"key":"10.1016\/j.retram.2022.103343_bib0099","article-title":"We will \u2018ROCK\u2019 you? The role of Rho kinase inhibitors in eye care","author":"Narayan","year":"2021","journal-title":"OPTICIANS"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318622000113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318622000113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:39:26Z","timestamp":1762821566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318622000113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2452318622000113"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2022.103343","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2022.103343","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103343"}}